235 results on '"Pardanani, Animesh D."'
Search Results
2. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
3. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
4. 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events
5. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients
6. Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases
7. The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events
8. Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90
9. A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count
10. Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms
11. De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases
12. TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)
13. ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis
14. ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival
15. Patient Outcomes after Initial High Dose Versus Low Dose Romiplostim for Inpatient Management of Immune Thrombocytopenia
16. C3+ and C3- Warm Autoimmune Hemolytic Anemias: A Comparison of Clinical Characteristics and Treatment Outcomes
17. Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
18. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
19. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
20. Phase 1/-2 study of pomalidomide in myelofibrosis
21. Chronic basophilic leukemia: a distinct clinico-pathologic entity?
22. Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
23. Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance
24. Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series
25. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis
26. Primary Myelodysplastic Syndromes
27. Cytogenetic findings in WHO‐defined polycythaemia vera and their prognostic relevance.
28. Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent
29. Type 1/like CalrMutation in Momelotinib-Treated Patients with Myelofibrosis Is the Most Prominent Predictor of Drug Survival and Longevity without Transplant
30. ASXL1Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis
31. TP53Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)
32. Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2 -Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases
33. International Prognostic Scoring System–independent cytogenetic risk categorization in primary myelofibrosis
34. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
35. The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
36. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations
37. Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis
38. Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies
39. TP53 mutations and Polymorphisms in Primary Myelofibrosis,
40. Phase1/-2 study of Pomalidomide in myelofibrosis
41. A JAK2 Germline Genetic Variation Is Associated with Shortened Survival in Primary Myelofibrosis: Clinical and JAK2V617F Allele Burden Correlates of rs12343867 SNP Genotype in 132 Cases.
42. Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis.
43. JAK2 Haplotype SNP Analysis in Essential Thrombocythemia: Clinical and JAK2V617F Allele Burden Correlates in 226 Patients.
44. Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years.
45. Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.
46. Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.
47. A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.
48. Significant in-Vitro Activity of a Novel JAK2 Inhibitor in Multiple Myeloma Associated with Preferential Cytotoxicity for CD45+ Myeloma Cells.
49. Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era.
50. Indolent Mastocytosis in 159 Adults: Smoldering but Not Bone Marrow Only Variant Is Prognostically Significant.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.